Fig. 2

ECM changes associated with increased lung cancer risk and premalignant progression. A Odds ratios for genes in the matrix risk signature. See Additional File 1: Table S1. B,C Matrix risk scores are significantly higher in tumor compared with non-tumor tissue in the TCGA (B, p=6.7E−12, Mann-Whitney U test) and NCI-MD cohorts (C, p=4.6E−10, Mann-Whitney U test). D,E ROC analysis of the matrix risk score in distinguishing between tumor and non-tumor tissue on the bootstrapped test data from the TCGA cohort (D, area under the curve (AUC)=1) and the NCI-MD cohort (E, area under the curve (AUC) = 0.89). F,G Expression scores for matrix risk signature genes with positive odds ratios (F) and negative odds ratios (G) in specific lung cell types from tumor and non-tumor tissue. H Matrix risk score in regressive (Reg.) and progressive (Prog.) pre-invasive squamous carcinoma in situ lesions. p=0.023, Mann-Whitney U test. I Matrix Risk Score in young and old lungs in the absence of tumors, p=0.0020, two-sided Student’s t test